Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XOMA vs IOVA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XOMA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

XOMA Overall Winner 6-Pillar Tally: XOMA 3 – 2 IOVA (1 Tie) Matrix Metrics: XOMA 7 – 3 IOVA

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Iovance Biotherapeutics, Inc. (IOVA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas IOVA carries 67.5/100 (BUY) at $7.55 (N/M Forward P/E, -60.8% operating margin).

  • Composite vs. Pillar Nuance: While IOVA currently prints a higher short-term Unified Composite Score (67.5/100 BUY vs. XOMA 55.8/100 HOLD), XOMA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-3.9% vs. -60.8% operating margin) and revenue trajectory (-22.6% vs. +80.1% YoY).
  • Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile IOVA is in a Breakdown options structure phase (RSI 32.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XOMA vs IOVA
XOMA NASDAQ Head-to-Head Winner
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06
IOVA NASDAQ
Iovance Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.55
-2.64% 1D
Market Cap $3.5B
TTM Revenue $379M
Forward P/E N/M
Beta / 30D Vol 1.58β · 144% Vol
Unified Composite Score
67.5 / 100 BUY
Tech 68.0 Fund 73.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 32
RSI-14: 32.2 · SMA20: $10.38 · SMA50: $11.31

6-Pillar Scorecard Institutional Category Breakdown (XOMA 3 – 2 IOVA)

Columns: Metric · XOMA · IOVA
1. Valuation Multiples XOMA
Forward P/E 21.5x N/M
Trailing P/E 28.2x N/M
PEG Ratio N/M N/M
EV / Revenue 16.1x 9.3x
2. Growth & Scale IOVA
Revenue Growth (YoY) -22.6% +80.1%
Earnings Growth (YoY) +207.9% +0.0%
TTM Revenue (USD) $49M $379M
Market Cap $781.8M $3.5B
3. Profitability & Quality XOMA
Gross Margin 99.0% 53.2%
Operating Margin -3.9% -60.8%
Net Profit Margin 69.6% -58.2%
Return on Equity (ROE) 34.2% -29.1%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) $8.3M EBITDA -$216M
Cash Flow Margin 17.1% EBITDA Mgn -57.0%
Net Cash / Leverage $7.79 Book/Sh · 34.2% ROE $13M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IOVA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 101.5% (100th %ile) 83.9% (25th %ile)
Put/Call OI Skew N/A 0.58x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XOMA (7) vs IOVA (3)
Institutional Metric XOMA IOVA Criterion Row Edge
Market Capitalization
Scale
$781.8M $3.5B Larger Scale IOVA
Trailing P/E Ratio
Valuation
28.2x N/M Lower Multiple XOMA
Forward P/E Ratio
Valuation
21.5x N/M Lower Multiple XOMA
Revenue Growth (YoY)
Growth
-22.6% +80.1% Higher Growth IOVA
Operating Margin (TTM)
Profitability
-3.9% -60.8% Higher Margin XOMA
Net Profit Margin
Profitability
69.6% -58.2% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
34.2% -29.1% Higher ROE XOMA
52-Week Range Position
Momentum
78% ($22–$45) 41% ($2–$15) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
0.68β · 37% Vol 1.58β · 144% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
55.8 / 100 (HOLD) 67.5 / 100 (BUY) Higher Composite IOVA
Trailing 12M Revenue (USD)
Operating Scale
$49M $379M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.0% 53.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.1x EV/Rev N/M PEG · 9.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) -$216M ($13M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IOVA +10.69 pp
XOMA: -3.81% · IOVA: +6.88%
3M Horizon XOMA +0.15 pp
XOMA: +9.34% · IOVA: +9.19%
6M Horizon IOVA +20.53 pp
XOMA: +34.26% · IOVA: +54.79%
1Y Horizon IOVA +43.03 pp
XOMA: +24.6% · IOVA: +67.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs IOVA. Trailing 12-month operating profitability (XOMA -3.9% vs IOVA -60.8%) and valuation multiples (XOMA 21.5x vs IOVA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x
IOVA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$379M
Gross Margin53.2%
Op. Margin-60.8%
ROE / Fwd P/E-29.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IOVA BREAKDOWN
33d in phase · OBV NEUTRAL
Current IV 83.9%
IV Percentile 25th %ile
Put/Call OI Skew 0.58x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact IOVA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IOVA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.5B market capitalization and -60.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XOMA vs IOVA Key Questions & Quantitative Answers

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Iovance Biotherapeutics, Inc. (IOVA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas IOVA carries 67.5/100 (BUY) at $7.55 (N/M Forward P/E, -60.8% operating margin). Composite vs. Pillar Nuance: While IOVA currently prints a higher short-term Unified Composite Score (67.5/100 BUY vs. XOMA 55.8/100 HOLD), XOMA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-3.9% vs. -60.8% operating margin) and revenue trajectory (-22.6% vs. +80.1% YoY). Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile IOVA is in a Breakdown options structure phase (RSI 32.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IOVA leads the Growth & Scale pillar: XOMA posts -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin), compared with IOVA at +80.1% YoY revenue growth and +0.0% YoY earnings growth on $379M TTM revenue (53.2% gross margin, -60.8% operating margin). On trailing 12-month operating scale, XOMA generates $49M in USD-normalized revenue versus $379M for IOVA. In operating R&D and SG&A reinvestment, XOMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IOVA.

XOMA screens cheaper on headline valuation multiples. XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin), whereas IOVA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.3x EV/Revenue (-57.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XOMA (34.2% ROE) versus IOVA (-29.1% ROE) capital efficiency.

In options market volatility and institutional positioning, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk). By comparison, IOVA carries 83.9% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.58x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.58β · 144% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.